Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

593

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: 50 mg PB1023
DRUG: 70 mg PB1023
DRUG: 100 mg PB1023
DRUG: Placebo (0.9% Sodium Chloride)
DRUG: Victoza®
OTHER: Diet and Exercise
DRUG: Metformin
DRUG: Sulfonylurea
DRUG: Metformin and Sulfonylurea

Sponsor

PhaseBio Pharmaceuticals Inc.